SEC Info - Allergan Inc - ‘15-15D’ on 4/16/15

SEC Info℠

Home

Help

Please Sign In

Allergan Inc – ‘15-15D’ on 4/16/15

On: Thursday, 4/16/15, at 7:02pm ET · As of: 4/17/15 · Effective: 4/17/15 · Accession #: 1193125-15-133687 · File #: 333-183092

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 4/17/15  Allergan Inc                      15-15D      4/17/15    1:12K                                    RR Donnelley/FA

Notice of Suspension of Duty to File Reports — Form 15
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 15-15D      Form 15                                             HTML     10K

This is an HTML Document rendered as filed. [ Alternative Formats ]

Form 15

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 15

CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION

UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934

OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 333-183092

ALLERGAN, INC.

(Exact Name of Registrant as Specified in its Charter)

Morris Corporate Center

400 Interpace Parkway

Parsippany, New Jersey 07054

(862) 261-7000

(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

$250,000,000 1.350% Notes due 2018

$350,000,000 2.800% Notes due 2023

(Title of each class of securities covered by this Form)

N/A

(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:


Rule 12g-4(a)(1)		¨
Rule 12g-4(a)(2)		¨
Rule 12h-3(b)(1)(i)		¨
Rule 12h-3(b)(1)(ii)		¨
Rule 15d-6		x

Approximate number of holders of record as of the certification or notice date: $250,000,000 1.350% Notes due 2018: seventy; $350,000,000 2.800% Notes due 2023: sixty

Pursuant to the requirements of the Securities Exchange Act of 1934, Allergan, Inc. has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.


Date: April 16, 2015	ALLERGAN, INC.

	By:	/s/ *A. Robert D. Bailey*
	Name:	A. Robert D. Bailey
	Title:	President and Chairman of the Board

Dates Referenced Herein and Documents Incorporated by Reference

This ‘15-15D’ Filing	Date	Other Filings

Filed as of / Effective on:	4/17/15	15-15D
Filed on:	4/16/15	15-15D
		List all Filings

↑Top

Filing Submission 0001193125-15-133687 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Allergan Inc – ‘15-15D’ on 4/16/15

On: Thursday, 4/16/15, at 7:02pm ET · As of: 4/17/15 · Effective: 4/17/15 · Accession #: 1193125-15-133687 · File #: 333-183092

Previous ‘15-15D’: ‘15-15D’ on 4/17/15 · Latest ‘15-15D’: This Filing

Notice of Suspension of Duty to File Reports — Form 15Filing Table of Contents

This is an HTML Document rendered as filed. [ Alternative Formats ]

Dates Referenced Herein and Documents Incorporated by Reference

Notice of Suspension of Duty to File Reports — Form 15
Filing Table of Contents